The Alzheimer Disease Research Center (ADRC) at the University of Southern California (USC) focuses on Reducing Alzheimer and Vascular Contributions to Cognitive Impairment in Diverse Populations. The ADRC views brain health in the broad context of the neurobiology and psychology of aging, with Alzheimer Disease (AD) and cerebrovascular disease (CVD) as the two major causes of pathological cognitive decline. We have built an interdisciplinary team to bridge basic science to clinical trials, well before the term """"""""translational"""""""" research became popular. This renewal application includes three projects which strengthen translational research. Our populations include a 15-year prospective study of Caucasians enrolled in the Long Beach Longitudinal Study (LBLS), a 10-year prospective study of Hispanics in the community-based Los Angeles Latino Eye Study (LALES) and a newly funded, community-based Chinese American Eye Study (CHES). Several affiliated cohorts include the Aging Brain Program Project (PLChui) and the Progesterone and Brain Aging and Alzheimer Disease (PI: R. Brinton). During the next five years, we will focus on the following overarching goals: 1) Clarify the pathological and phenotypic interactions between AD and CVD, 2) Increase recruitment and retention of minority subjects from LALES, CHES, and the surrounding neighborhood, 3) Promote clinical trials and translational research in memory and aging at USC, and 4) Continue active participation in national initiatives, including National Alzheimer Coordinating Center (NACC), Alzheimer Disease Cooperative Study (ADCS), Alzheimer Disease Neuroimaging Initiative (ADNI), and Genome Wide Association Study (GWAS). The ADRC comprise 6 Cores (Administration, Data, Clinical, Education, Pathology, and Imaging) and 3 Projects: Zelinski (Course of Cognitive Change in Late Adulthood), Brinton/Pike (Novel NeuroSERMs and NeuroSARMs for protection against Alzheimer pathology), and Zheng (Cognitive Impairment in a Chinese American Community).
Alzheimer and cerebrovascular disease are the two most important threats to cognitive health in aging. Epidemiologic studies indicate that vascular risks factors increase the risk of AD. Many vascular risk factors are eminently treatable. Reduction of vascular risk factors would decrease the risk of cognitive decline.
|Soosman, Steffan K; Joseph-Mathurin, Nelly; Braskie, Meredith N et al. (2016) Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiol Aging 47:201-209|
|Kammen, Alexandra; Law, Meng; Tjan, Bosco S et al. (2016) Automated retinofugal visual pathway reconstruction with multi-shell HARDI and FOD-based analysis. Neuroimage 125:767-79|
|Forrester, Sarah N; Gallo, Joseph J; Smith, Gwenn S et al. (2016) Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia. Am J Geriatr Psychiatry 24:117-25|
|Barnes, Samuel R; Ng, Thomas S C; Montagne, Axel et al. (2016) Optimal acquisition and modeling parameters for accurate assessment of low Ktrans blood-brain barrier permeability using dynamic contrast-enhanced MRI. Magn Reson Med 75:1967-77|
|Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2016) Post Hoc Analyses of ApoE Genotype-Defined Subgroups in ClinicalÂ Trials. J Alzheimers Dis 50:1205-15|
|Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9|
|Finch, Caleb E; Shams, Sara (2016) Apolipoprotein E and Sex Bias in Cerebrovascular Aging of Men and Mice. Trends Neurosci 39:625-37|
|Crawford, Karen L; Neu, Scott C; Toga, Arthur W (2016) The Image and Data Archive at the Laboratory of Neuro Imaging. Neuroimage 124:1080-3|
|Bilousova, Tina; Miller, Carol A; Poon, Wayne W et al. (2016) Synaptic Amyloid-Î² Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. Am J Pathol 186:185-98|
|Halliday, Matthew R; Rege, Sanket V; Ma, Qingyi et al. (2016) Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 36:216-27|
Showing the most recent 10 out of 394 publications